TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36109035

Group type: EXPERIMENTAL
Intervention: Structured, multidisciplinary and personalised post‐ICU care
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2250
Study: 36161640

Group type: EXPERIMENTAL
Intervention: USG-guided FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Landmark approach FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Number of subjects: 100
Study: 32379071

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 843
Study: 35737144

Group type: EXPERIMENTAL
Intervention: Chaihu plus Longgu Muli decoction with five-element music therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Escitalopram tablets (Control)
Number of subjects: 120
Study: 32925478

Group type: EXPERIMENTAL
Intervention: AED-guided CPR
Number of subjects: 42

Group type: COMPARATOR
Intervention: dispatcher-assisted CPR
Number of subjects: 42
Study: 35698101

Group type: EXPERIMENTAL
Intervention: 15 mg oxycodone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Untrained study team (arm A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trained to maximize placebo responses (arm B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Trained to minimize placebo responses (arm C)
Number of subjects: 96
Study: 32598090

Group type: EXPERIMENTAL
Intervention: Exercise and information
Number of subjects: 70

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 70
Study: 35420291

Group type: EXPERIMENTAL
Intervention: Hypoxic newborns (n=21) with cord blood pH below 7.25
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=21) with cord blood pH above 7.25
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hypoxic newborns (n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 42
Study: 33441058

Group type: EXPERIMENTAL
Intervention: Nebulized amphotericin B twice daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nebulized amphotericin B 3 times daily
Number of subjects: 84
Study: 34402029

Group type: EXPERIMENTAL
Intervention: GBCS model (10-year sex-specific CVD risk prediction model including age, systolic blood pressure, use of antihypertensive medication, smoking, and diabetes)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Framingham model
Number of subjects: 15000

Group type: COMPARATOR
Intervention: China-PAR model
Number of subjects: 15000
Study: 34406318

Group type: EXPERIMENTAL
Intervention: Risk score based on five variables (age, female gender, NYHA functional classification score >3, left atrial diameter, body mass index)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Derivation and test models
Number of subjects: 1742
Study: 32721213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 35383116

Group type: EXPERIMENTAL
Intervention: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 5 mL every 2 weeks (cohort 08)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 10 mL every 2 weeks (cohort 09)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OrienX010 (combined cohorts)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Injected lesions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Non-injected lesions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Distant lung metastases
Number of subjects: 26
Study: 34556320

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 36280151

Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated radiation therapy (1.8 Gy daily to PTV + 0.6 Gy boost to GTV, total 45 Gy to PTV and 60 Gy to GTV in 25 fractions over 5 weeks)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (2 Gy daily to PTV, total 44 Gy to PTV and 60 Gy to GTV in 30 fractions over 6 weeks)
Number of subjects: 266
Study: 33887120

Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient intervention based on individualized haemodynamic assessment and teleconsultations.
Number of subjects: 605

Group type: COMPARATOR
Intervention: Standard care group (control).
Number of subjects: 605
Study: 32468646

Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg orally once daily for 26 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg orally once daily for another 26 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nilotinib (both doses)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 34598314

Group type: EXPERIMENTAL
Intervention: CAF+CM (n=25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CAF+XDM (n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CAF (control group, n=25)
Number of subjects: 75
Study: 36014916

Group type: EXPERIMENTAL
Intervention: 200 mg of DHA from algal oil per day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo capsule per day
Number of subjects: 160
Study: 33043737

Group type: EXPERIMENTAL
Intervention: AdaptivCRT algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional CRT programming
Number of subjects: 0
Study: 33210335

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 84

Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 84
Study: 32128938

Group type: EXPERIMENTAL
Intervention: Illness uncertainty
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Active and avoidant coping strategies
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Illness uncertainty through avoidant coping strategies
Number of subjects: 263
Study: 35442755

Group type: EXPERIMENTAL
Intervention: ET with ibandronate 50 mg once daily for 3 years
Number of subjects: 1116

Group type: COMPARATOR
Intervention: ET alone (control)
Number of subjects: 1116
Study: 33986453

Group type: EXPERIMENTAL
Intervention: Ag NPs at 15 mL/L
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ag NPs at 12.5 mL/L
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zn NPs at 7.5 mL/L
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ag NPs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zn NPs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ag NPs treated leaves extract at 3000 µg/mL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acetone extracts from leaves treated with Ag NPs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acetone extracts from leaves treated with both nanomaterials
Number of subjects: 70

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 70
Study: 32418039

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cyclosporin (CsA)
Number of subjects: 83
Study: 34301673

Group type: EXPERIMENTAL
Intervention: Gender transformative intervention (10-session participatory intervention)
Number of subjects: 1265
Study: 33538513

Group type: EXPERIMENTAL
Intervention: Instagram image sharing
Number of subjects: 106
Study: 35564623

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVBFB) plus Treatment as Usual (TAU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) only
Number of subjects: 61
Study: 34357722

Group type: EXPERIMENTAL
Intervention: Immunomodulatory drug based on muramilpeptides
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment with no muramilpeptides‐based agent
Number of subjects: 20
Study: 32087620

Group type: EXPERIMENTAL
Intervention: PSI group (TKA assisted by patient-specific instrumentation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional group (conventional TKA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 35405100

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) with 25-30 mm Hg pressure
Number of subjects: 268

Group type: COMPARATOR
Intervention: Sham elastic compression stockings (≤10 mm Hg pressure)
Number of subjects: 268
Study: 33760035

Group type: EXPERIMENTAL
Intervention: Highest quartile of remnant cholesterol (quartile 4)
Number of subjects: 3812
Study: 32242541

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (9-month duration) including weekly classroom education, after-school cooking classes, and online materials
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study: 35710336

Group type: EXPERIMENTAL
Intervention: REACH-HF intervention at Beacon Sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: REACH-HF multicentre trial
Number of subjects: 0
Study: 35103343

Group type: COMPARATOR
Intervention: Itraconazole pulse therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Acitretin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combined itraconazole/acitretin therapy
Number of subjects: 135
Study: 32324898

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Umifenovir
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Number of drugs used in the hospital
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Underlying basic diseases
Number of subjects: 217
Study: 35986372

Group type: EXPERIMENTAL
Intervention: Early essential newborn care (EENC) with skin-to-skin contact for 30 min
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Early essential newborn care (EENC) with skin-to-skin contact for 60 min
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Early essential newborn care (EENC) with skin-to-skin contact for 90 min
Number of subjects: 720

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 720
Study: 34900605

Group type: EXPERIMENTAL
Intervention: Tailored internet-based intervention (IBI) program
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (TAU+)
Number of subjects: 360
Study: 36657487

Group type: EXPERIMENTAL
Intervention: Baseline number of chronic diseases
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Baseline multimorbidity (3 or more chronic diseases)
Number of subjects: 2157
Study: 33504021

Group type: EXPERIMENTAL
Intervention: ACTN3 R577X genotype in men
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: ACTN3 R577X genotype in women
Number of subjects: 281
Study: 36318852

Group type: EXPERIMENTAL
Intervention: Prostatilen AC (Zinc arginyle-glycinate dihydrochloride)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Prostatilen (reference drug)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Prostatilen AC
Number of subjects: 98

Group type: COMPARATOR
Intervention: Prostatilen
Number of subjects: 98
Study: 34217337

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 480

Group type: COMPARATOR
Intervention: Plasma‐Lyte 148
Number of subjects: 480

Group type: COMPARATOR
Intervention: Compound Sodium Lactate
Number of subjects: 480
Study: 34096389

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 50
Study: 36217147

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation (RDI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cotton roll isolation (CRI)
Number of subjects: 93
Study: 32269026

Group type: EXPERIMENTAL
Intervention: Online video series with sexual health information via pamphlet
Number of subjects: 300

Group type: COMPARATOR
Intervention: Pamphlet with sexual health information only
Number of subjects: 300
Study: 34229475

Group type: EXPERIMENTAL
Intervention: Brief manual standardized stress acupuncture (MSSA) combined with abbreviated Cognitive Behavioral Therapy (ACBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACBT alone
Number of subjects: 0
Study: 32718191

Group type: EXPERIMENTAL
Intervention: Sourdough (SD) bread
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Baker's yeast (BY) bread
Number of subjects: 17
Study: 33105552

Group type: EXPERIMENTAL
Intervention: GluS (Glutathione Synthesis)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GluReS (Glutathione and Resveratrol Synthesis)
Number of subjects: 2
Study: 34607760

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus anterior plane block (SAPB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no SAPB)
Number of subjects: 70
Study: 33764299

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unavailable and unresponsive conditions
Number of subjects: 0
Study: 32722659

Group type: EXPERIMENTAL
Intervention: MR stimulation (fludrocortisone 0.4 mg + placebo)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: NMDA-R stimulation (placebo + D-cycloserine 250 mg)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: MR and NMDA-R stimulation (both drugs)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 35574927

Group type: EXPERIMENTAL
Intervention: True bilateral cerebellar iTBS
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham bilateral cerebellar iTBS
Number of subjects: 70
Study: 33030042

Group type: EXPERIMENTAL
Intervention: 8-week tinnitus-specific cognitive behavioral therapy (CBT) and personalized sound therapy via smartphone application
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (waitlisted patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatment and control groups
Number of subjects: 30
Study: 35331009

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 2842

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 2842

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2842
Study: 32018189

Group type: EXPERIMENTAL
Intervention: Sleep extension (mean duration 6.60 hours/night)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Habitual sleep (mean duration 5.58 hours/night)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Higher sleep efficiency
Number of subjects: 8
Study: 35815489

Group type: EXPERIMENTAL
Intervention: Pre‐bent Kirschner wire
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prévot nail
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Kirschner wire
Number of subjects: 32
Study: 33131786

Group type: EXPERIMENTAL
Intervention: Cervical mobilisations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (motionless manual contact)
Number of subjects: 40
Study: 32605387

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with a defibrillator (CRT-D)
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) only
Number of subjects: 1818
Study: 35798455

Group type: EXPERIMENTAL
Intervention: Mavacamten, 5 mg daily, titrated up to 15 mg based on LVOT gradient and LV ejection fraction
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 112
Study: 34312088

Group type: EXPERIMENTAL
Intervention: Long testosterone (12.5 mg/day testosterone gel for 56 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Short testosterone (12.5 mg/day testosterone gel for 10 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Long testosterone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Short testosterone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 35356997

Group type: EXPERIMENTAL
Intervention: Histamine skin prick
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo skin prick
Number of subjects: 60
Study: 33297402

Group type: EXPERIMENTAL
Intervention: Deep learning methods based on a convolutional neural network and cost-effective computer vision technology
Number of subjects: 1240
Study: 35341320

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) intravenous injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 54
Study: 33965945

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥180 s)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Early cord clamping (≤60 s)
Number of subjects: 540
Study: 32345275

Group type: EXPERIMENTAL
Intervention: Inadequate health literacy
Number of subjects: 15728

Group type: EXPERIMENTAL
Intervention: Problematic health literacy
Number of subjects: 15728

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 15728

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 15728

Group type: EXPERIMENTAL
Intervention: Poor self-assessed health
Number of subjects: 15728

Group type: EXPERIMENTAL
Intervention: Sickness absence compensation benefits
Number of subjects: 15728
Study: 33128533

Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 11
Study: 33487261

Group type: EXPERIMENTAL
Intervention: Dry extract of ginger (5% gingerol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 20
Study: 36407493

Group type: EXPERIMENTAL
Intervention: Nanoemulsion oral solution (60,000 IU cholecalciferol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Soft gelatin capsules (60,000 IU cholecalciferol)
Number of subjects: 24
Study: 33580564

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (T) + Exercise (Ex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P) + Exercise (Ex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 0
Study: 32459660

Group type: EXPERIMENTAL
Intervention: Instruction + feedback group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Instruction only group
Number of subjects: 12
Study: 34252575

Group type: EXPERIMENTAL
Intervention: Balance-based attentive rehabilitation of attention (BARAN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Aerobic exercise and running (active control)
Number of subjects: 29
Study: 32510462

Group type: EXPERIMENTAL
Intervention: 3-month behavior change program via mobile app (TravelVu Plus)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard TravelVu app
Number of subjects: 254
Study: 36413078

Group type: EXPERIMENTAL
Intervention: Tailored use of defunctioning stoma based on personalized risk of anastomotic leak (mAFOR Score >= 2) and early stoma closure (days 8-12 postoperatively)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Systematic use of defunctioning stoma for 2-3 months post-operatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tailored use of defunctioning stoma
Number of subjects: 200

Group type: COMPARATOR
Intervention: Systematic use of defunctioning stoma
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 200
Study: 32940823

Group type: EXPERIMENTAL
Intervention: Inclusive physical activity (IPA) program
Number of subjects: 45
Study: 32066973

Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt substitute (75% NaCl and 25% KCl)
Number of subjects: 2376

Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt substitute
Number of subjects: 2376

Group type: COMPARATOR
Intervention: Control group (regular salt)
Number of subjects: 2376
Study: 34995745

Group type: EXPERIMENTAL
Intervention: 10-hour simulation training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1-hour simulation training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vascular surgeons (control group)
Number of subjects: 48
Study: 34733561

Group type: EXPERIMENTAL
Intervention: Physiotherapy (12 sessions, twice a week for 6 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (80 mg of methylprednisolone and 1 ml of lidocaine 2% in two stages, 21 days apart)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of physiotherapy and corticosteroid injection (80 mg of methylprednisolone and 1 ml of lidocaine 2%, followed by 6 sessions of physiotherapy twice a week for 3 weeks)
Number of subjects: 96
Study: 35194862

Group type: EXPERIMENTAL
Intervention: E-cigarette starter pack with weekly allocations of nicotine containing e-liquid for 4 weeks (flavours: menthol, fruit, tobacco; strengths: 12 mg/mL and 18 mg/mL)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care intervention (very brief advice and a leaflet signposting to the local stop smoking service)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: E-cigarette starter pack
Number of subjects: 480
Study: 34113094

Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (1mg) in stable COPD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (1mg) in AECOPD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo in stable COPD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo in AECOPD
Number of subjects: 72
Study: 32265532

Group type: EXPERIMENTAL
Intervention: More years of schooling (including college)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher intelligence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age of finishing school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More years of schooling
Number of subjects: 0
Study: 34542801

Group type: EXPERIMENTAL
Intervention: Adult-associated BMI scores
Number of subjects: 194153

Group type: EXPERIMENTAL
Intervention: Childhood-associated BMI scores
Number of subjects: 194153
Study: 33226660

Group type: COMPARATOR
Intervention: WALK8 (8 minutes every 60 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SIT (9 hours of prolonged sitting)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: WALK3 (3 minutes of brisk walking every 30 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: WALK5 (5 minutes of brisk walking every 45 minutes)
Number of subjects: 16